February 21, 2024
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for ASCT: Primary Results of the Perseus Trial
Pieter Sonneveld, MD, PhD (Erasmus MC Cancer Institute — Rotterdam, Netherlands) discusses the effectiveness of Daratumumab (DARA SC) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as induction/consolidation therapy as opposed to VRd alone in myeloma patients eligible for autologous stem cell transplantation.